Introduction
The use of peripheral stem cells (PSCs) for hematopoietic engraftment is becoming increasingly common, and these are now used in approximately 30% of pediatric transplants with matched related donors. 1 The larger numbers of hematopoietic progenitor cells that can be obtained following growth-factor mobilization and apheresis may result in faster neutrophil recovery, decreased transfusion requirements and faster immune reconstitution compared with bone marrow. [2] [3] [4] [5] [6] However, PSCs contain at least one log more T cells than bone marrow, which theoretically could increase the risk of GVHD. 7 Some studies have noted no increased risk of acute GVHD with matched sibling donor PSCT, despite the increase in T cells in PSCs. 2, 4, 8 This may be as a result of the shift from Th1 to Th2 -type lymphocytes with altered cytokine pattern as a result of G-CSF mobilization. 9, 10 Most studies have shown an increased risk of chronic GVHD, which is more likely to be refractory and extensive, resulting in increased late mortality. 8, [11] [12] [13] Although some studies reported a benefit from chronic GVHD with presumptive increased graft vs leukemia (GVL) effect for patients with high-risk leukemias, this benefit is nullified by higher mortality from GVHD in lower risk patients. 14 A recent retrospective analysis compared pediatric patients who received PSCs or bone marrow from matched related donors, and demonstrated increased non-relapse mortality with PSCs, with more deaths from chronic GVHD. 1 Unrelated donor BMT is associated with an increased risk of both acute and chronic GVHD, and these concerns may be heightened with the increased T cell dose in peripheral blood. Despite the significant use of PSCs for matched sibling donor transplants, there have been few reports of PSC transplant for unrelated donors.
Elimination or reduction of CD3 þ cells in PSCs may allow retention of the benefits of rapid engraftment kinetics, while reducing the risk of extensive chronic GVHD. Positive selection of CD34 þ stem cells results in approximately 3-4 log reduction of CD3 þ cells, with decreased risks of GVHD, but increased risks of risks of graft failure and relapse. 15, 16 An addition of defined dose of CD3 þ cells at the time of infusion may alleviate the problem of graft rejection, yet allow for GVL and reduced chronic GVHD. To retain the advantages of PSCs, but reduce the risks of graft failure and GVHD, we developed a protocol to 'partially' T deplete PSCs by positive selection of CD34 þ cells and an addback of CD3 þ cells at the time of infusion.
Patients and methods
Patients were eligible for this study if they had acute leukemias in first remission having failed primary induction therapy, or second remission, or chronic leukemias, and lacked an HLA matched sibling donor. Unrelated donor search was performed through the National Marrow Donor Program, if a related donor mismatched at one or two antigens was not available. Donors had to be willing and able to provide mobilized peripheral stem cells collected by apheresis. Donors underwent peripheral stem cell mobilization with G-CSF 10 ug/kg/day subcutaneously for five days. The Children's Hospital of Philadelphia Institutional Review Board approved the protocol, and parent or patient gave written consent.
Histocompatibility testing
Before transplantation, HLA typing on the patient and potential donors was performed by DNA-based methodology for A, B, C, DRB1 and DQB1 loci. HLA-C was performed at the low/intermediate level. HLA A, B, DRB1 and DQB1 were analyzed at the allele level by highresolution typing. Loci A, B and DRB1 were first analyzed at the intermediate resolution level by a reverse SSOP (sequence specific oligonucleotide probes) methodology (RELIt Dynal Inc.) and thereafter, depending on the typing, appropriate kits (Genovision Inc.) were selected for high-resolution typing. HLA-DQB1 typing was directly performed at the high-resolution level using 'One Lambda' SSP kits. These methodologies have been previously tested and validated. 17, 18 Conditioning and GVHD prophylaxis Conditioning included thiotepa 5 mg/kg days À6, À5, cyclophosphamide 60 mg/kg days À4, À3, and total body irradiation 1200 cGy/6 fractions days À2, À1, 0. Patients with CML in first chronic phase received anti-lymphocyte globulin 1.5 mg/kg days -2, -1, 0 for additional immunosuppression. Lung shielding after 800 cGy was performed for the last 14 patients, when concerns arose regarding engraftment syndrome and pulmonary toxicity.
GVHD prophylaxis included cyclosporine infusion beginning day 1 to achieve serum levels of 200-400 ng/dl. This was changed to oral tacrolimus when tolerated, as per institutional practice to improve compliance, with levels maintained between 4-12 ng/ml. Weaning commenced at day þ 100 in the absence of GVHD. Methylprednisolone 1 mg/kg in 2 divided doses was begun at day þ 8 for the last 14 patients to alleviate potential engraftment syndrome. This was rapidly weaned in the absence of GVHD once engraftment occurred.
Supportive care
All patients were in HEPA filtered private rooms, and given prophylactic acyclovir, trimethoprim/sulfamethoxazole, gut decontamination with oral amoxicillin and gentamicin, and fluconzaole. Intravenous gamma globulin 400 mg/kg was given every other week for three months. CMV antigenemia was monitored weekly once engraftment occurred. No growth factors were used post SCT.
Peripheral stem cell processing and CD3 þ addback CD34 þ selection was performed with Isolex 300i, which resulted in an average T cell depletion of 4.2. logs. The positive fraction had an average purity of 94%, and CD3 þ cells obtained from the negative fraction were added to the positively selected product at the time of infusion to achieve the defined CD3 þ dose of 5 Â 10 5 /kg. The remaining portion of the negative fraction was cryopreserved in multiple aliquots for donor lymphocyte infusions, if needed.
Post transplantation evaluation
The day of engraftment was the first of 3 consecutive days on which the neutrophil count was X500 ul. Chimerism was documented by variable nucleotide tandem repeats (VNTRs). Patients with CML had quantitative bcr-abl monitoring by polymerase chain reaction every 3 months starting six months post BMT.
Patients who engrafted were evaluable for acute GVHD, and patients who survived more than 100 days were evaluable for chronic GVHD. Graft vs host disease was graded according to established criteria. 19 Acute GVHD was treated with methylprednisolone or prednisone 1-2 mg/kg and tapered weekly according to response. For patients who did not respond, additional agents were used, including Daclizumab, and mycophenolate mofetil.
Statistical analysis
All statistical analyses were performed in STATA 8.0. (STATA Corp., College Park, TX). The cut-off date for analysis was 3/1/05. For all patients, an event was defined as relapse or non-relapse mortality, and the Kaplan-Meier model was used for survival analysis.
Results
Twenty-five patients were enrolled on this study from 2002-2004. One patient's cells were poorly viable on dye exclusion (Trypan blue) testing upon receipt, and this did not allow for manipulation. This patient was excluded from further analysis of engraftment and GVHD. She received haploidentical PSCs for engraftment.
Clinical characteristics of the 24 evaluable patients are shown in Table 1 . All patients with acute leukemias were in remission. One patient with MDS had failed a prior syngeneic transplant, and another patient had secondary AML following therapy for ALL. One patient with ALL developed pancytopenia and histiocytosis for which he was referred for transplantation. Donors were matched for 12 patients (Table 2) Event free survival for all patients enrolled was 50%, with 12 patients surviving in remission 14-36 months post SCT (median, 25) ( Figure 1 ). All survivors have Karnofsky or Lansky activity scores of 100. CML patients were bcrabl negative by PCR less than six months from PSCT, without GVHD. There were two relapses in AML patients at 3 and 18 months. The patient who relapsed at 18 months achieved a second remission with chemotherapy, and was 95% donor by VNTRs before a second non-myeloablative transplant using cryopreserved residual peripheral stem cells.
Non-relapse mortality (NRM) was 41.7%, with deaths occurring 32-85 days (median, 50) after SCT. Infection and pulmonary toxicity were responsible for NRM, and included CMV (2), idiopathic interstitial pneumonitis (IIP) (6), HHV6 (2), Pseudomonas (1). Both patients who died from CMV pneumonitis were seropositive with seronegative donors; one developed pneumonitis at day þ 20, with negative antigenemia and the second had persistent antigenemia, despite therapy with ganciclovir and foscarnet. CMV was noted on biopsy samples of both patients. Patients with HHV6 had positive PCR from blood, with one patient PCR positive in both CSF and pleural fluid. These patients had other symptoms consistent with HHV6, including encephalitis, skin rash and pneumonitis. Patients with IIP did not have any organisms identified by pathology, PCR or culture from bronchoalveolar lavage or thoracoscopic biopsy. Viral studies on these patients included RSV, parainfluenza, HHV6, adenovirus, and CMV. These patients developed capillary leak and oxygen requirement at the onset of engraftment. Three patients may have had risk factors that predisposed them to IIP; one had streptococcus viridans sepsis one week prior to development of IIP, one patient had prolonged mechanical ventilation during reinduction therapy, and one patient had a prior myeloablative transplant. Only one of these patients had lung shielding during TBI.
Acute GVHD developed in 17 patients, but was grade III-IV in only two (8.3%). All patients had skin involvement, with gut involvement in one. In the patient with grade IV GVHD it was concomitant with HHV6 disease. Chronic GVHD developed in eight of 13 (61.5%) evaluable patients, but was limited to skin involvement only in seven, and skin and perioral involvement in one. No patient developed extensive chronic GVHD. Two patients received additional therapy, including Daclizumab and mycophenolate mofetil. There has been resolution in seven patients; one remains on weaning therapy with complete resolution of skin involvement.
Immune function studies, including immunoglobulins and lymphocyte subsets, were performed at 241-384 days post SCT and were available for a subset of surviving patients. These data are summarized in Table 3 . No infections requiring intravenous antibiotics were observed after day 100.
Discussion
Most series have shown that unmodified PSCs for matched sibling donor transplants result in faster engraftment, but 20 There were no differences in either acute or chronic GVHD between the two groups. Other studies in adult patients with leukemias initially showed no differences in outcome or acute or chronic GVHD between bone marrow and PSC unrelated donor transplants. 21, 22 However, a recently published follow-up confirmed the increased risk of extensive chronic GVHD in PSC recipients, and no survival advantage compared with bone marrow recipients. 23 In another non-randomized study of patients with acute leukemias, lower survival was noted in ALL patients with PSCs compared with bone marrow. 24 Unlike other studies, the incidence of acute GVHD was higher in ALL patients who received PSCs.
T cell depletion may decrease the risk of GVHD but is associated with a higher risk of graft failure and relapse. These major problems may be dependent upon type and degree of T cell depletion, as T cell depletion of bone marrow with narrow specificity antibodies may not have these disadvantages. 25 Our previous study with partially T cell depleted bone marrow for unrelated and partially matched related donors demonstrated a graft rejection rate of o5%, and relapse rate that was comparable to T replete grafts. 26 The optimal number and type of T cells in a PSC graft to ensure engraftment and maintain potential graft vs leukemia effect is unknown. In addition, other factors, including the dose of CD34 þ cells/kg and HLA disparity, must be included as factors in engineering the ideal PSC graft. 27, 28 T cell depletion of PSCs may be accomplished by positive selection methods, such as CD34 þ selection, which has the advantage of eliminating B cells that may cause EBV-associated lymphoproliferative disease. The largest experience using CD34 þ selected PSCs comes from studies of haploidentical related donors. [29] [30] [31] However, the extensive T cell depletion by this method may increase the risk of graft failure due to depletion of cells that may facilitate engraftment. A recent study compared three groups that received unrelated donor products, including bone marrow, unselected PSCs, and CD34 þ selected PSCs. A higher rate of graft rejection occurred with the CD34 þ selected PSCs; engraftment occurred in 95% of patients who received unselected PSCs, in contrast to 78% engraftment in recipients of CD34 þ selected PSCs (Po0.001). 21 Bornhauser et al. used CD34 þ selected PSCs for unrelated donors, with an infusion of 1 Â 10 5 /kg CD3 þ cells at the time of initial infusion or delayed until day þ 21. Graft failure occurred in 16% of patients 15 and an increased rate of relapse and infectious complications was also noted. In a series of unrelated donor PSCT in 31 children with leukemias, Lang et al. used CD34 þ selected PSCs 31 without post transplant immunosuppression. Five patients did not engraft initially, but subsequently engrafted with additional immunosuppression. Nonengraftment was associated with a CD34 þ dose of o10 Â 10 6 /kg. Although engraftment was achieved in all patients, the prolonged pancytopenia obviously increased infectious risks. Although 'mega' doses of CD34 þ cells, at least 10 Â 10 6 /kg, are associated with engraftment in CD34 þ selected PSCs, 30 ,31 patients on our study engrafted with cell doses that were much lower.
We aimed to replicate the results with partial T cell depletion of bone marrow by adding back a defined dose of T cells to PSCs. The addition of T cells has been shown to reduce the risk of graft failure, but the optimum number and type for addback is unknown. In a study by Urbano-Ispizua there was a correlation between T cell dose and engraftment in patients receiving matched sibling donor PSCs. 32 In that study, the number of T cells below which there was an increased risk of graft failure was 2 Â 10 5 /kg, as 14.8% of patients experienced graft failure when given less than this, compared with only 1% graft failure for those who received more. This study was complicated, however, by the variability of conditioning, as non-engraftment was higher in CML patients who received busulfan regimens. 32 Another study using matched sibling donors used the Ceprate system for CD34 þ selection that resulted in approximately 3 log T depletion. A median of 4.2 Â 10 5 /kg CD3 þ cells was infused, with a range from 1 to 20 Â 10 5 /kg. 33 Both cyclosporine and methylprednisolone were used for GVHD prophylaxis, and all patients engrafted. GVHD developed in six of 20 patients, and was less than grade III, with chronic GVHD observed in only one of sixteen patients at risk with short follow up. 33 Based upon these studies, we decided to add back a slightly higher dose, 5 Â 10 5 /kg CD3 þ , and use cyclosporine prophylaxis post transplant. All our patients engrafted, and despite HLA mismatches in almost half our patients, severe GVHD occurred in only two patients. However, chronic GVHD was observed in 66% of evaluable patients, which lends concern about the dose of CD3 þ cells. Unlike studies in which no modification of PSCs was done, we were successful in limiting the extent of chronic GVHD as all patients have activity scores of 100, and extensive involvement was not observed.
There is tremendous diversity in the composition of a PSC graft in terms of CD34 þ and CD3 þ content. In particular, the dose of CD34 þ cells in an unselected PSC graft may impact upon the development of chronic GVHD and outcome. One study found favorable effects in relapse free survival when CD34 þ doses were greater than 3 Â 10 6 /kg in a T depleted PSC graft. 27 However, this has not been substantiated in other studies, with increased chronic GVHD and decreased survival with high doses of CD34 þ . In one study a negative effect of doses greater than 3 Â 10 6 /kg, with 75% of patients alive who received doses 1 to 3 Â 10 6 /kg, in contrast to 52% for those who received larger doses. 34 Both Mohty and Zaucha et al. noted increased chronic GHVD with doses higher than 8 Â 10 6 /kg. 28, 35 Our study was too limited to evaluate the effect of CD34 þ dose in outcome and chronic GVHD. Unlike CD34 þ , the dose of CD3 þ does not appear to correlate with either acute or chronic GVHD in an unmodified graft. 28, 36 CD34 þ selection with T cell addback with unrelated donors N Bunin et al Engraftment syndrome has been described primarily in autologous PSCT, and it may be a significant cause of morbidity and mortality in children. 37 It is characterized by fever without infectious etiology, rash that can mimic GVHD, weight gain and pulmonary infiltrates. 38 The incidence of this syndrome in PSCT may be related to a higher cell dose and faster engraftment, as it usually occurs with the onset of engraftment. 39, 40 The release of proinflammatory cytokines, including IL-1 and TNF-a, have been implicated in its development. 41 There are few reports of engraftment syndrome with allogeneic PSCT, but steroids may be used successfully. 42 Treatment with steroids was initiated prophylactically when we became concerned about morbidity from engraftment syndrome, but the efficacy of this intervention was unclear in our study. Concerns regarding engraftment syndrome and pulmonary toxicity led to closure of the study.
Even at one year post SCT, our patients had a CD4 þ / CD8 þ o2, with elevated B and NK cells. Profound immunodeficiency and slow immune reconstitution, with an increased risk of infectious complications, develop after T depleted grafts, including CD34 þ selected PSCs. Despite monitoring and prompt therapy with foscarnet or ganciclovir, CMV disease may develop with rapid onset of fatal pneumonitis. 43 We also experienced early onset of CMV pneumonitis in one patient, before antigenemia became positive, as well as CMV that did not respond to combined antiviral therapy. Prophylactic therapy in the highest risk group, CMV positive recipients with serology negative donors may help prevent this complication, but patients will remain at risk for the development of later onset disease. 44, 45 In addition, early onset of CMV drug resistance has been noted in other studies of T depleted recipients, 46 with the lack of an immune response allowing for high viral replication during therapy. Pediatric patients may be at particularly higher risk for this complication. 47 One patient with grade IV GVHD developed HHV6 disease concomitant with the onset of GVHD. HHV6 may initiate or exacerbate GVHD in T depleted grafts. 31, 48 Partial T cell depletion as accomplished with CD34 þ selection with an addback of CD3 þ cells at the time of infusion for recipients of unrelated donor or partially matched related donor PSCT may allow for durable engraftment without loss of GVL. 'Megadoses' of CD34 þ cells are not needed to accomplish engraftment, as in selection without the addition of CD3 þ cells. Although chronic GVHD was observed, it was limited and not extensive as reported in series of unselected PSCT. However, engraftment syndrome and profound immunodeficiency resulting in viral infections remain a concern. Newer separation devices now allow removal of CD3 þ cells, which is more consistent with our previous methods of T depletion, and we have begun to use this technology. As more information becomes available regarding subsets of T cells that mediate engraftment or GVHD, and technology for graft processing improves, we will be able to better 'engineer' the PSC product to take advantage of its unique properties.
